Myrlosar Comp (Losartan Potassium, Hydrochlorothiazide)

Losartan potassium and hydrochlorothiazide, the active ingredients in Myrlosar Comp, are an angiotensin II receptor blocker and a thiazide diuretic presented as an oral tablet for systemic use. They treat hypertension in adult patients by lowering blood pressure and reducing fluid overload, through complementary mechanisms.

GNH USA supplies Myrlosar Comp as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality, safety and regulatory compliance across all markets. Our distribution network guarantees timely delivery and reliable product availability for healthcare providers.

Myrlosar Comp, a combination antihypertensive, acts on the renin‑angiotensin system and renal sodium handling to control high blood pressure.

Hypertension: lowers systolic and diastolic blood pressure in patients with essential hypertension. Cardiovascular risk reduction: helps decrease the risk of stroke and heart attack associated with uncontrolled hypertension. Renal protection in diabetes: provides kidney protective effects in patients with diabetic nephropathy when used as part of a comprehensive treatment plan.

Myrlosar Comp may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness - Headache - Increased urination - Electrolyte disturbances (e.g., low potassium) - Fatigue

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Acute kidney injury - Hyperkalemia - Significant drop in blood pressure (hypotension)

Before prescribing Myrlosar Comp, clinicians should consider several safety precautions.

Monitor blood pressure: ensure adequate control and avoid hypotension. Assess renal function: check serum creatinine and eGFR prior to initiation and periodically. Check electrolytes: especially potassium and sodium levels during therapy. Use caution in pregnancy: avoid unless clearly needed, as safety data are limited. Review concomitant medications: avoid combining with other potassium‑sparing agents or ACE inhibitors without supervision. Store at ambient temperature: keep in the original container, protect from moisture and light.

Myrlosar Comp can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Potassium‑sparing diuretics: risk of hyperkalemia. - ACE inhibitors or other ARBs: may cause excessive renal impairment. - Lithium: increased lithium toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect. - Other antihypertensives: may lead to additive blood‑pressure lowering. - Antidiabetic agents: blood‑glucose levels may require adjustment.